Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
Recruiting
Phase 2
Interventional Study
Cell Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age \> 18 years
* Histologically confirmed,
* primary, previously untreated,
* superficial basal cell carcinoma (sBCC) not arising on the face or scalp, ≤ 15 mm (large axis)
Exclusion Criteria:
* BCC of the face or scalp
* BCC of non-superficial subtype
* BCC with large axis…
Contacts
Henri Montaudie, PhD
+33492036223
CONTACT